摘要
FKI- 0 0 76 A、B和 C是从真菌培养液中筛选 Azole类抗真菌活性增强剂过程中获得的 ,每 6 mm纸片 10μg FKI- 0 0 76 A、B或 1.0μg FKI- 0 0 76 C就显示增强活性。真菌 Talaromyces sp.FKI- 0 0 76培养 5 d后 ,经有机溶媒提取 ,常压 ODS柱层析和制备 HPL C柱层析分离 ,得到 FKI- 0 0 76 A、B和 C纯品。又经过测定其HR- MS、UV、IR、1 H- NMR、1 3C- NMR、DEPT、1 H- 1 H COSY、HMQC和 HMBC等光谱数据。将 FKI- 0 0 76 A的结构定为 BK 2 2 3- A,FKI- 0 0 76 B的结构定为 vermistatin,FKI- 0 0 76 C的结构定为 deoxyfunicone。
During our screening programme for synergist of azoles antifungal antibiotics, we found the FKI 0076A, B and C which exhibited 10, 10 and 1.0μg/6mm paper disk of synergistic activity to azoles. The culture broth of Talaromyces sp. FKI 0076 for 5 days in shaking state was extracted by organic solvent, isolated by Open ODS Column and HPLC, active compounds FKI 0076A, B and C were obtained. Based on spectral data of HR MS, UV, 1 H NMR, 13 C NMR, DEPT, 1 H 1H COSY, HMQC and HMBC, FKI 0076A, B and C were identified as BK 223 A, vermistatin and deoxyfunicone,respectively.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2001年第2期89-93,133,共6页
Chinese Journal of Antibiotics